Allergic rhinitis
Conditions
Interventions
Control group:Posterior Nasal Nerve Ablation Technology
Treatment group:Complete transection of sphenopalatine neurovascular bundle
Sponsors
The Third Affiliated Hospital Sun Yat-sen University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients voluntarily participate in the trial and sign an informed consent form; 2. Patients are 18-65 years old, in line with the diagnostic criteria for Allergic rhinitis; 3. Patients with poor efficacy of standardized drug treatment; 4. Patients are not willing to undergo specific immunotherapy or poor effectiveness of specific immunotherapy; 5. Patients are not willing to undergo medication treatment; 6. Patients are willing to undergo surgical treatment; 7. Patients are able to communicate well with researchers and comply with the entire experimental requirements.
Exclusion criteria
Exclusion criteria: 1. Patients who refuse to sign an informed consent form to participate in the trial; 2. Patients under 18 years old or over 66 years old; 3. Patients with uncontrolled or acute exacerbation of asthma; 4. Patients with mental and psychological disorders; 5. Patients with severe systemic diseases; 6. Patients with Nasal polyp; 7. Patients whouse systemic steroid within the past month, and use local nasal steriod during the perioperative period; 8. Patients with unreasonable treatment effect requirements or poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rhinoconjunctivitis Quality of Life Questionnaire;nose/eye symptom score (total symptom score TNSS/VAS scale); | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse reactions and events;Blood routine and cytokines;Nasal resistance; | — |
Countries
China
Contacts
Public ContactYang Qintai
The Third Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed